469 related articles for article (PubMed ID: 15163209)
21. Nitroreductase-based GDEPT.
Denny WA
Curr Pharm Des; 2002; 8(15):1349-61. PubMed ID: 12052212
[TBL] [Abstract][Full Text] [Related]
22. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954.
Drabek D; Guy J; Craig R; Grosveld F
Gene Ther; 1997 Feb; 4(2):93-100. PubMed ID: 9081711
[TBL] [Abstract][Full Text] [Related]
23. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals.
Bhaumik S; Sekar TV; Depuy J; Klimash J; Paulmurugan R
Gene Ther; 2012 Mar; 19(3):295-302. PubMed ID: 21753794
[TBL] [Abstract][Full Text] [Related]
24. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
[TBL] [Abstract][Full Text] [Related]
25. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase.
Anlezark GM; Melton RG; Sherwood RF; Wilson WR; Denny WA; Palmer BD; Knox RJ; Friedlos F; Williams A
Biochem Pharmacol; 1995 Aug; 50(5):609-18. PubMed ID: 7669063
[TBL] [Abstract][Full Text] [Related]
26. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.
Grove JI; Lovering AL; Guise C; Race PR; Wrighton CJ; White SA; Hyde EI; Searle PF
Cancer Res; 2003 Sep; 63(17):5532-7. PubMed ID: 14500391
[TBL] [Abstract][Full Text] [Related]
27. Phthalimide analogs of CB 1954: synthesis and bioactivation.
Mehta LK; Hobbs S; Chen S; Knox RJ; Parrick J
Anticancer Drugs; 1999 Sep; 10(8):777-83. PubMed ID: 10573210
[TBL] [Abstract][Full Text] [Related]
28. Ablation of central nervous system progenitor cells in transgenic rats using bacterial nitroreductase system.
Kwak SP; Malberg JE; Howland DS; Cheng KY; Su J; She Y; Fennell M; Ghavami A
J Neurosci Res; 2007 May; 85(6):1183-93. PubMed ID: 17304579
[TBL] [Abstract][Full Text] [Related]
29. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector.
Chen MJ; Green NK; Reynolds GM; Flavell JR; Mautner V; Kerr DJ; Young LS; Searle PF
Gene Ther; 2004 Jul; 11(14):1126-36. PubMed ID: 15164095
[TBL] [Abstract][Full Text] [Related]
30. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
Hay MP; Gamage SA; Kovacs MS; Pruijn FB; Anderson RF; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2003 Jan; 46(1):169-82. PubMed ID: 12502371
[TBL] [Abstract][Full Text] [Related]
31. Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954.
Jarrom D; Jaberipour M; Guise CP; Daff S; White SA; Searle PF; Hyde EI
Biochemistry; 2009 Aug; 48(32):7665-72. PubMed ID: 19580253
[TBL] [Abstract][Full Text] [Related]
32. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954.
Djeha AH; Hulme A; Dexter MT; Mountain A; Young LS; Searle PF; Kerr DJ; Wrighton CJ
Cancer Gene Ther; 2000 May; 7(5):721-31. PubMed ID: 10830719
[TBL] [Abstract][Full Text] [Related]
33. Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo.
White CL; Menghistu T; Twigger KR; Searle PF; Bhide SA; Vile RG; Melcher AA; Pandha HS; Harrington KJ
Gene Ther; 2008 Mar; 15(6):424-33. PubMed ID: 18079753
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
Palmer BD; Wilson WR; Anderson RF; Boyd M; Denny WA
J Med Chem; 1996 Jun; 39(13):2518-28. PubMed ID: 8691449
[TBL] [Abstract][Full Text] [Related]
35. Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle.
Guise CP; Grove JI; Hyde EI; Searle PF
Gene Ther; 2007 Apr; 14(8):690-8. PubMed ID: 17301844
[TBL] [Abstract][Full Text] [Related]
36. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954.
McNeish IA; Green NK; Gilligan MG; Ford MJ; Mautner V; Young LS; Kerr DJ; Searle PF
Gene Ther; 1998 Aug; 5(8):1061-9. PubMed ID: 10326029
[TBL] [Abstract][Full Text] [Related]
37. Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy.
Bailey SM; Knox RJ; Hobbs SM; Jenkins TC; Mauger AB; Melton RG; Burke PJ; Connors TA; Hart IR
Gene Ther; 1996 Dec; 3(12):1143-50. PubMed ID: 8986441
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and evaluation of 4-substituted analogues of 5-[N,N-bis (2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase.
Atwell GJ; Boyd M; Palmer BD; Anderson RF; Pullen SM; Wilson WR; Denny WA
Anticancer Drug Des; 1996 Oct; 11(7):553-67. PubMed ID: 8921936
[TBL] [Abstract][Full Text] [Related]
39. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase.
Bilsland AE; Anderson CJ; Fletcher-Monaghan AJ; McGregor F; Evans TR; Ganly I; Knox RJ; Plumb JA; Keith WN
Oncogene; 2003 Jan; 22(3):370-80. PubMed ID: 12545158
[TBL] [Abstract][Full Text] [Related]
40. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
Hu L; Yu C; Jiang Y; Han J; Li Z; Browne P; Race PR; Knox RJ; Searle PF; Hyde EI
J Med Chem; 2003 Nov; 46(23):4818-21. PubMed ID: 14584930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
